Health and Healthcare

Schering-Plough Relief on Partner Earnings (SGP)

Schering-Plough Corp. (NYSE: SGP) is probably breathing a sigh of relief this morning after Merck’s earnings as it is partners with the drug giant on Vytorin and Zetia for cholesterol treatments.

The combined Vytorin & Zetia franchise was noted as having some $5.2 Billion in 2007 annual sales, with some $1.5 Billion being reported in the fourth quarter alone.

Merck did disclose some 50 lawsuits over these sales and noted that it is complying and cooperating with investigations.  But the good news is that the company’s guidance wasn’t sharply changed.

Schering-Plough has a large portion of its profits that come directly as a result of its Merck partnership.  It is still too early to get a solid read on Schering-Plough shares and obviously the situation can change based on Merck comments in their earnings conference call. 

So far shares are indicated up marginally for Schering-Plough at $19.20 after a $19.11 close yesterday.  Its 52-week trading range is $17.45 to $33.81, and shares were north of $26.00 at the start of 2008.

Jon C. Ogg
January 30, 2008

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.